Now trading at a price of $49.82, Intra-Cellular Therapies has moved 0.1% so far today.
Intra-Cellular Therapies returned gains of 9.0% last year, with its stock price reaching a high of $67.05 and a low of $42.01. Over the same period, the stock underperformed the S&P 500 index by -4.0%. As of April 2023, the company's 50-day average price was $53.54. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. Based in New York, NY, the mid-cap Health Care company has 561 full time employees. Intra-Cellular Therapies has not offered a dividend during the last year.
The Business Has Consistently Weak Margins:
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $246 | $61 | $22,813 | $83,803 | $250,314 | $365,837 |
| Gross Margins | -65906% | -254090% | -1014% | -341% | -105% | -54% |
| Operating Margins | -63101.0% | -243711.0% | -994.0% | -339.0% | -102.0% | -50.0% |
| Net Margins | -63102.0% | -243714.0% | -994.0% | -339.0% | -102.0% | -50.0% |
| Net Income (k) | -$155,127 | -$147,722 | -$227,006 | -$284,126 | -$256,256 | -$184,371 |
| Free Cash Flow (k) | -$118,560 | -$128,684 | -$230,340 | -$259,869 | -$270,964 | -$189,501 |
| Capital Expenditures | $391 | $700 | $267 | $325 | $778 | $89 |
| Net Current Assets (k) | $315,947 | $174,145 | $630,451 | $395,249 | $639,247 | $591,561 |
| Long Term Debt (k) | $0 | $0 | $0 | $0 | $0 | $0 |
Intra-Cellular Therapies does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-0.65. The average P/E ratio for the Health Care sector is 24.45. Furthermore, Intra-Cellular Therapies is likely overvalued compared to the book value of its equity, since its P/B ratio of 7.89 is higher than the sector average of 4.16.
Intra-Cellular Therapies Has an Average Rating of Buy:
The 12 analysts following Intra-Cellular Therapies have set target prices ranging from $59.0 to $100.0 per share, for an average of $77.83 with a buy rating. As of April 2023, the company is trading -31.2% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Intra-Cellular Therapies has an average amount of shares sold short because 3.2% of the company's shares are sold short. Institutions own 94.0% of the company's shares, and the insider ownership rate stands at 2.56%, suggesting a decent amount of insider shareholders. The largest shareholder is FMR, LLC, whose 12% stake in the company is worth $557,161,767.
